^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IGKC (Immunoglobulin Kappa Constant)

    i
    Other names: IGKC, Immunoglobulin Kappa Constant, HCAK1, Immunoglobulin Kappa (Invariant Region), Immunoglobulin Kappa Light Chain (VJ), Immunoglobulin Kappa Constant Region, Ig Kappa Chain C Region CUM, Ig Kappa Chain C Region ROY, Ig Kappa Chain C Region AG, Ig Kappa Chain C Region EU, Ig Kappa Chain C Region OU, Ig Kappa Chain C Region TI, Ig Kappa Chain C Region, IGKCD, Km
    3ms
    Single-cell transcriptomic analysis reveals key cell types and pathogenic genes associated with metastasis in pancreatic adenocarcinoma. (PubMed, Clin Exp Med)
    Furthermore, PTK6 was identified as a driver of PAAD proliferation, migration, and invasion. Collectively, our study elucidates TME-driven mechanisms of PAAD metastasis, identifies prognostic and therapeutic targets, and provides a framework for precision intervention.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • SPP1 (Secreted Phosphoprotein 1) • CD14 (CD14 Molecule) • LMO7 (LIM Domain 7) • APOE (Apolipoprotein E) • IGKC (Immunoglobulin Kappa Constant) • PTK6 (Protein Tyrosine Kinase 6)
    3ms
    Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. (PubMed, Nat Commun)
    Individuals with high expression levels of either FGA, SERPINE1, FGG, or F3 exhibit poorer survival, higher infiltration of Tregs, and lower infiltration of CD8+ cells. Results from this study suggest that CS-related genes play a role in PDAC genetic susceptibility and survival through specific immune cell infiltration.
    Journal
    |
    CD8 (cluster of differentiation 8) • SERPINE1 (Serpin Family E Member 1) • IGKC (Immunoglobulin Kappa Constant)
    4ms
    Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort. (PubMed, J Pers Med)
    Additional candidates, including B3GALT1, ZKSCAN4, and immunoglobulin transcripts, provided complementary insights but require further validation. These preliminary results highlight intra-stage heterogeneity in FIGO II CC and underscore the promise of molecular markers to improve risk assessment.
    Journal
    |
    IGHG1 (Immunoglobulin Heavy Constant Gamma 1) • IGKC (Immunoglobulin Kappa Constant)
    4ms
    Fractionated Gamma Knife Surgery: Long-Term Results and Patient Outcomes for Intracranial Lesions. (PubMed, Med J Islam Repub Iran)
    In this study, we examined various factors, including lesion levels from brain Magnetic Resonance Imaging findings, patient prognosis, and changes after f-GKS. Our results confirm those of previous studies, highlighting the significant role of noninvasive GKS in improving patient prognosis and reducing tumor size.
    Journal
    |
    IGKC (Immunoglobulin Kappa Constant)
    6ms
    Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer. (PubMed, NPJ Digit Med)
    Bulk RNA-seq deconvolution further supported the prognostic significance of low-grade-enriched subtypes. Our findings highlight the heterogeneity of the tumor microenvironment and provide new insights into immune evasion and therapeutic resistance in breast cancer.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • BRCA (Breast cancer early onset) • IGKC (Immunoglobulin Kappa Constant)
    9ms
    Integration of Bulk and Single-Cell Transcriptomics Reveals BCL2L14 as a Novel IGKC+ T Cell-Associated Therapeutic Target in Breast Cancer. (PubMed, J Inflamm Res)
    Our results underscore BCL2L14 as a potential driver within the novel T-cell subpopulation and a critical biomarker for breast cancer diagnosis. These findings provide a basis for developing advanced diagnostic tools and targeted therapies, which may ultimately enhance patient prognosis.
    Journal
    |
    IGKC (Immunoglobulin Kappa Constant) • MAPT (Microtubule Associated Protein Tau) • MAPT-AS1 (MAPT Antisense RNA 1)
    9ms
    Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis. (PubMed, Cancer Lett)
    LAIT and ICIs enhance NK cell-mediated antitumor responses via distinct yet complementary mechanisms, emphasizing their potential for synergistic use. These findings provide novel insights into NK cell modulation within the TME and support the development of combinatorial immunotherapy strategies.
    Journal • Checkpoint inhibition • IO biomarker
    |
    IGKC (Immunoglobulin Kappa Constant) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    9ms
    Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma. (PubMed, Clin Cancer Res)
    Integrating candidate blood and tumor immune-related biomarkers generated a baseline signature that maximizes the prediction of immunotherapeutic benefits in reference to the compartmental biomarker signatures.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD33 (CD33 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CCL3 (C-C Motif Chemokine Ligand 3) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • IGKC (Immunoglobulin Kappa Constant) • INPP5D (Inositol Polyphosphate-5-Phosphatase D)
    |
    Yervoy (ipilimumab)
    10ms
    Recombinant antibodies from clonally expanded cancer-associated plasma cells. (PubMed, Cancer Immunol Immunother)
    These tumors exhibited increased B cell receptor diversity, immunogenic mutation, and intratumoral heterogeneity. This study suggests the potential for discovering cancer-associated antibodies derived from intratumoral plasma cells.
    Journal
    |
    IGHG1 (Immunoglobulin Heavy Constant Gamma 1) • IGKC (Immunoglobulin Kappa Constant)
    12ms
    Single-Cell Sequencing Reveals PD-L1-Mediated Immune Escape Signaling in Lung Adenocarcinoma. (PubMed, J Cancer)
    Additionally, we identified 11 differentially expressed genes that could provide insights into the potential mechanisms of immune escape in patients with lung cancer. These findings offer promising molecular targets for the detection and treatment of immune escape in clinical settings.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MUC1 (Mucin 1) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7) • IGKC (Immunoglobulin Kappa Constant) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • NAPSA (Napsin A Aspartic Peptidase) • MYO6 (Myosin VI)
    |
    PD-L1 expression • PD-L1 negative
    1year
    A Novel Platinum-Resistance-related Gene Signature in Ovarian Cancer: Identification and Patient-derived Organoids Verification. (PubMed, Curr Cancer Drug Targets)
    The platinum-resistance-related gene signature (SLC22A2, TAP1, PC, MCM3, GTF2H2, FXYD5, SUPT6H, IGKC, and MATN2) is valuable for prognosis prediction and guidance of treatment choices for OC patients.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • IGKC (Immunoglobulin Kappa Constant) • TAP1 (Transporter 1) • MCM3 (Minichromosome maintenance complex component 3) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    cisplatin • dasatinib • midostaurin • MK-2206 • mitomycin • metformin
    over1year
    Prognostic Impact of Acute and Chronic Inflammatory Interleukin Signatures in the Tumor Microenvironment of Early Breast Cancer. (PubMed, Int J Mol Sci)
    This study highlights the complex interaction between acute and chronic inflammatory interleukins in breast cancer progression and prognosis. These findings provide insight into the prognostic relevance of interleukin expression patterns in breast cancer and may inform future therapeutic strategies targeting the immune-inflammatory axis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IGKC (Immunoglobulin Kappa Constant) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    PD-1 expression • CD8 expression